The line between educating healthcare professionals and wooing them can still be fuzzy, which is impacting what doctors ...
Despite an uptick in dealmaking and IPOs, a selective funding market and scientific setbacks are still pushing some biotechs ...
Merck is the most exposed to risk from generic competition in the short term, but AbbVie, Johnson & Johnson, Sanofi and ...
Drugmakers are pouring billions into U.S. production, but building enough plants won’t matter without enough skilled workers ...
Ai3Bio recently emerged from stealth with preclinical programs aimed at what it believes could be a root cause of autoimmune ...
A new report argues that more flexible eligibility criteria could widen pharma’s clinical trial pool without sacrificing ...
CEOs can make or break a company. And new leaders at three of pharma’s largest drugmakers are taking over with little room for error. All three leaders took the ...
The FDA is continuing its push to expedite early-stage research for drug developers and is now accepting applications for a new pilot program aimed at accelerating U.S. clinical trials. The primary ...
Right now is “singularly, the most exciting moment” in Daiichi Sankyo’s 100-year history, said Ken Keller, CEO and president of the company’s U.S. business and head of its global oncology unit. Riding ...
Attempting to bring new medicines to market is an inherently risky endeavor, with sponsors ultimately failing more than 90% of the time. But rare disease development is even harder; there are fewer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results